These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24598096)

  • 41. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
    [No Abstract]   [Full Text] [Related]  

  • 42. Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry.
    Mytych DT; Park JK; Kim J; Barger TE; Boshier A; Jawa V; Kuter DJ
    Br J Haematol; 2020 Sep; 190(6):923-932. PubMed ID: 32311075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE; Rose MJ
    Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury.
    Watanabe R; Tabayashi T; Tomikawa T; Sagawa M; Anan-Nemoto T; Kimura Y; Takahashi Y; Tokuhira M; Otaki S; Oi H; Sawano M; Sugiyama S; Kizaki M
    Int J Hematol; 2017 Jan; 105(1):100-103. PubMed ID: 27709451
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Romiplostim or standard of care in patients with immune thrombocytopenia.
    Kuter DJ; Rummel M; Boccia R; Macik BG; Pabinger I; Selleslag D; Rodeghiero F; Chong BH; Wang X; Berger DP
    N Engl J Med; 2010 Nov; 363(20):1889-99. PubMed ID: 21067381
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
    Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
    BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
    Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
    Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
    [No Abstract]   [Full Text] [Related]  

  • 48. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531).
    Pullarkat VA; Gernsheimer TB; Wasser JS; Newland A; Guthrie TH; de Wolf JT; Stewart R; Berger D
    Am J Hematol; 2009 Aug; 84(8):538-40. PubMed ID: 19569197
    [No Abstract]   [Full Text] [Related]  

  • 49. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 50. Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
    Suntsova EV; Maschan AA; Baydildina DD; Kalinina II; Petrova UN; Pshonkin AV; Novichkova GA
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27704. PubMed ID: 30854783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Romiplostim dose response in patients with immune thrombocytopenia.
    Perez-Ruixo JJ; Green B; Doshi S; Wang YM; Mould DR
    J Clin Pharmacol; 2012 Oct; 52(10):1540-51. PubMed ID: 22167563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
    Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
    Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
    Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Successful management of primary immune thrombocytopenia with romiplostim during open heart surgery in a hemodialysis patient].
    Nishikii H; Kurita N; Kusakabe M; Yokoyama Y; Kato T; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
    Rinsho Ketsueki; 2019; 60(1):28-32. PubMed ID: 30726820
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of romiplostim in patients with chronic idiopathic thrombocytopenic purpura during perioperative period.
    Ramakrishna R; Rehman A; Ramakrishna S; Alexander W; Yeo WW
    Intern Med J; 2015 Jul; 45(7):718-24. PubMed ID: 25904300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
    Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C
    Blood Coagul Fibrinolysis; 2012 Jun; 23(4):331-4. PubMed ID: 22343685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2009 Mar; (71):20-5. PubMed ID: 19200304
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Romplostim in the treatment of immune thrombocytopenic purpura at a tertiary hospital].
    Riu Viladoms G; Creus Baró N; Estefanell Tejero A; Ribas Sala J
    Farm Hosp; 2012; 36(5):434-7. PubMed ID: 22871365
    [No Abstract]   [Full Text] [Related]  

  • 59. Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study.
    Schipperus M; Kaiafa G; Taylor L; Wetten S; Kreuzbauer G; Boshier A; Seesaghur A
    Drug Saf; 2019 Jan; 42(1):77-83. PubMed ID: 30232740
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
    Selleslag D; Bird R; Altomare I; Giagounidis A; Janssens A; Pabinger I; Pullarkat V; Wei H; Kreuzbauer G
    Eur J Haematol; 2015 Feb; 94(2):169-76. PubMed ID: 25039799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.